<!DOCTYPE html>
        <html lang="en">
        <head>
          <meta charset="UTF-8" />
          <meta name="viewport" content="width=device-width, initial-scale=1.0" />
          <title>MinMaxMuscle | ARA-290 (Cibinetide)</title>
          <meta name="description" content="Curated source summaries for ARA-290 (Cibinetide)." />
          <link rel="stylesheet" href="../assets/css/style.css" />
        </head>
        <body>
          <header>
            <div class="nav-container">
              <div class="logo">
                <img src="../assets/img/logo.png" alt="MinMaxMuscle Logo" />
                <span>MINMAXMUSCLE</span>
              </div>
              <nav class="desktop-nav">
                <a href="../index.html">Home</a>
                <a href="../training.html">Training</a>
                <a href="../nutrition.html">Nutrition</a>
                <a href="../peptides.html">Peptides</a>
                <a href="../coaching.html">Coaching</a>
                <a href="../contact.html">Contact</a>
              </nav>
              <div class="hamburger" id="hamburger">
                <span></span>
                <span></span>
                <span></span>
              </div>
            </div>
            <div class="mobile-menu" id="mobileMenu">
              <a href="../index.html">Home</a>
              <a href="../training.html">Training</a>
              <a href="../nutrition.html">Nutrition</a>
              <a href="../peptides.html">Peptides</a>
              <a href="../coaching.html">Coaching</a>
              <a href="../contact.html">Contact</a>
            </div>
          </header>
          <main>
            <section class="hero">
              <h1>ARA-290 (Cibinetide)</h1>
              <p>Automated source summaries for educational review. Verify claims with qualified professionals.</p>
            </section>
            <section class="peptide-source">
  <h2>Source</h2>
  <p><a href="https://en.wikipedia.org/wiki/Cibinetide" rel="noopener noreferrer" target="_blank">https://en.wikipedia.org/wiki/Cibinetide</a></p>
  <ul>
    <li>Main page</li><li>Contents</li><li>Current events</li><li>Random article</li><li>About Wikipedia</li><li>Contact us</li><li>Help</li><li>Learn to edit</li><li>Community portal</li><li>Recent changes</li><li>Upload file</li><li>Special pages</li><li>Donate</li><li>Create account</li><li>Log in</li><li># Contents</li><li>(Top)</li><li>1 References</li><li># Cibinetide</li><li>Article</li><li>Talk</li><li>Read</li><li>Edit</li><li>View history</li><li>What links here</li><li>Related changes</li><li>Permanent link</li><li>Page information</li><li>Cite this page</li><li>Get shortened URL</li><li>Download QR code</li><li>Download as PDF</li><li>Printable version</li><li>Wikidata item</li><li>(4S)-5-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(1S)-1-carboxy-2-hydroxyethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-oxo-4-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]pentanoic acid</li><li>1208243-50-8</li><li>91810664</li><li>DB13006</li><li>35013013</li><li>9W5677JKDA</li><li>D11218</li><li>ChEMBL3545305</li><li>Interactive image</li><li>C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H]1CCC(=O)N1</li><li>InChI=1S/C51H84N16O21/c1-22(2)17-30(47(84)65-32(19-36(53)71)48(85)66-33(20-68)49(86)67-34(21-69)50(87)88)63-40(77)24(5)57-41(78)25(7-6-16-56-51(54)55)59-43(80)29(11-15-39(75)76)62-46(83)31(18-23(3)4)64-45(82)27(8-12-35(52)70)60-44(81)28(10-14-38(73)74)61-42(79)26-9-13-37(72)58-26/h22-34,68-69H,6-21H2,1-5H3,(H2,52,70)(H2,53,71)(H,57,78)(H,58,72)(H,59,80)(H,60,81)(H,61,79)(H,62,83)(H,63,77)(H,64,82)(H,65,84)(H,66,85)(H,67,86)(H,73,74)(H,75,76)(H,87,88)(H4,54,55,56)/t24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34-/m0/s1</li><li>Key:WZTIQQBMSJTRBR-WYKNNRPVSA-N</li><li>Cibinetide ( INN Tooltip International Nonproprietary Name ; USAN Tooltip United States Adopted Name ; developmental code name ARA-290 ) is an erythropoietin receptor agonist which is under development for the treatment of a variety of different medical conditions . [ 1 ] [ 2 ] [ 3 ] [ 4 ] It was also under development for the treatment of depressive disorders , but development for this indication was discontinued. [ 1 ] The drug is under development by Araim Pharmaceuticals. [ 1 ] [ 2 ] Modified derivatives with a longer duration of action have also been developed. [ 5 ]</li><li># References</li><li>^ a b c d .mw-parser-output cite.citation{font-style:inherit;word-wrap:break-word}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .citation:target{background-color:rgba(0,127,255,0.133)}.mw-parser-output .id-lock-free.id-lock-free a{background:url("//upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-limited.id-lock-limited a,.mw-parser-output .id-lock-registration.id-lock-registration a{background:url("//upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-subscription.id-lock-subscription a{background:url("//upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .cs1-ws-icon a{background:url("//upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg")right 0.1em center/12px no-repeat}body:not(.skin-timeless):not(.skin-minerva) .mw-parser-output .id-lock-free a,body:not(.skin-timeless):not(.skin-minerva) .mw-parser-output .id-lock-limited a,body:not(.skin-timeless):not(.skin-minerva) .mw-parser-output .id-lock-registration a,body:not(.skin-timeless):not(.skin-minerva) .mw-parser-output .id-lock-subscription a,body:not(.skin-timeless):not(.skin-minerva) .mw-parser-output .cs1-ws-icon a{background-size:contain;padding:0 1em 0 0}.mw-parser-output .cs1-code{color:inherit;background:inherit;border:none;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;color:var(--color-error,#bf3c2c)}.mw-parser-output .cs1-visible-error{color:var(--color-error,#bf3c2c)}.mw-parser-output .cs1-maint{display:none;color:#085;margin-left:0.3em}.mw-parser-output .cs1-kern-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}@media screen{.mw-parser-output .cs1-format{font-size:95%}html.skin-theme-clientpref-night .mw-parser-output .cs1-maint{color:#18911f}}@media screen and (prefers-color-scheme:dark){html.skin-theme-clientpref-os .mw-parser-output .cs1-maint{color:#18911f}} "Cibinetide - Araim Pharmaceuticals" . AdisInsight . 28 June 2022 . Retrieved 23 October 2024 .</li><li>^ a b c "Delving into the Latest Updates on Cibinetide with Synapse" . Synapse . 8 October 2024 . Retrieved 23 October 2024 .</li><li>^ Peng B, Kong G, Yang C, Ming Y (February 2020). "Erythropoietin and its derivatives: from tissue protection to immune regulation" . Cell Death Dis . 11 (2) 79. doi : 10.1038/s41419-020-2276-8 . PMC 6997384 . PMID 32015330 .</li><li>^ Winicki NM, Nanavati AP, Morrell CH, Moen JM, Axsom JE, Krawczyk M, et al. (2023). "A small erythropoietin derived non-hematopoietic peptide reduces cardiac inflammation, attenuates age associated declines in heart function and prolongs healthspan" . Frontiers in Cardiovascular Medicine . 9 1096887. doi : 10.3389/fcvm.2022.1096887 . PMC 9889362 . PMID 36741836 .</li><li>^ Liu G, Liang J, Li W, Jiang S, Song M, Xu S, et al. (2024). "The protective effect of erythropoietin and its novel derived peptides in peripheral nerve injury". International Immunopharmacology . 138 112452. doi : 10.1016/j.intimp.2024.112452 .</li><li>v</li><li>t</li><li>e</li><li>See here instead.</li><li>Agonists: ARA-290</li><li>Asialo erythropoietin</li><li>Carbamylated erythropoietin</li><li>CNTO-530</li><li>Darbepoetin alfa</li><li>Epoetin alfa</li><li>Epoetin beta</li><li>Epoetin delta</li><li>Epoetin epsilon</li><li>Epoetin gamma</li><li>Epoetin kappa</li><li>Epoetin omega</li><li>Epoetin theta</li><li>Epoetin zeta</li><li>Erythropoietin (EPO)</li><li>Erythropoietin-Fc</li><li>Methoxy polyethylene glycol-epoetin beta (CERA/Mircera)</li><li>Peginesatide</li><li>Pegol sihematide (EPO-018B)</li><li>Agonists: Filgrastim</li><li>Granulocyte colony-stimulating factor</li><li>Lenograstim</li><li>Leridistim</li><li>Lipegfilgrastim</li><li>Nartograstim</li><li>Pegfilgrastim</li><li>Pegnartograstim</li><li>Agonists: Ecogramostim</li><li>Granulocyte macrophage colony-stimulating factor</li><li>Milodistim</li><li>Molgramostim</li><li>Regramostim</li><li>Sargramostim</li><li>Antibodies: Mavrilimumab</li><li>Namilumab</li><li>Otilimab</li><li>Agonists: Cilmostim</li><li>Interleukin-34</li><li>Lanimostim</li><li>Macrophage colony-stimulating factor</li><li>Mirimostim</li><li>Kinase inhibitors: Agerafenib</li><li>Agonists : Eltrombopag</li><li>Pegacaristim</li><li>Promegapoietin</li><li>Romiplostim</li><li>Avatrombopag</li><li>Lusutrombopag</li><li>Thrombopoietin (THPO, MGDF)</li><li>Agonists: Albinterferon</li><li>Interferon alpha (interferon alfa, IFN-α)</li><li>Interferon alfa ( IFNA1 , IFNA2 , IFNA4 , IFNA5 , IFNA6 , IFNA7 , IFNA8 , IFNA10 , IFNA13 , IFNA14 , IFNA16 , IFNA17 , IFNA21 )</li><li>Interferon alfa 2a</li><li>Interferon alfa 2b</li><li>Interferon alfa n1</li><li>Interferon alfacon-1</li><li>Interferon alpha-n3</li><li>Interferon beta (IFN-β) ( IFNB1 , IFNB3 )</li><li>Interferon beta 1a</li><li>Interferon beta 1b</li><li>Interferon kappa (IFN-ε/κ/τ/ζ, IFNK)</li><li>Interferon omega (IFN-ω, IFNW1)</li><li>Peginterferon alfa-2a</li><li>Peginterferon alfa-2b</li><li>Antibodies: Anifrolumab</li><li>Faralimomab</li><li>MEDI-545</li><li>Rontalizumab</li><li>Sifalimumab</li><li>Decoy receptors: Bifarcept</li><li>Agonists: Interferon gamma (IFN-γ)</li><li>Interferon gamma 1b</li><li>Antibodies: Emapalumab</li><li>Fontolizumab</li><li>See IL-28R (IFNLR) here instead.</li><li>Abrocitinib</li><li>Baricitinib</li><li>Deuruxolitinib</li><li>Filgotinib</li><li>Momelotinib</li><li>Oclacitinib</li><li>Peficitinib</li><li>Ruxolitinib</li><li>Tofacitinib (tasocitinib)</li><li>Upadacitinib</li><li>Atiprimod</li><li>AZD-1480</li><li>CHZ868</li><li>Cucurbitacin I (elatericin B, JSI-124)</li><li>CYT387</li><li>Lestaurtinib</li><li>NSC-7908</li><li>NSC-33994</li><li>Pacritinib</li><li>SD-1008</li><li>Cercosporamide</li><li>Decernotinib (VX-509)</li><li>Ritlecitinib</li><li>TCS-21311</li><li>WHI-P 154</li><li>ZM-39923</li><li>ZM-449829</li><li>Deucravacitinib</li><li>Additional cytokines: Cardiotrophin 1 (CT-1)</li><li>FMS-like tyrosine kinase 3 ligand (FLT3L)</li><li>Leukemia/leukocyte inhibitory factor (LIF)</li><li>Oncostatin M (OSM)</li><li>Thymic stromal lymphopoietin (TSLP)</li><li>Additional cytokine receptor modulators: Emfilermin</li><li>Midostaurin</li><li>Quizartinib</li><li>Sorafenib</li><li>Sunitinib</li><li>Experimental drugs</li><li>Hendecapeptides</li><li>Articles with short description</li><li>Short description is different from Wikidata</li><li>Drugs missing an ATC code</li><li>Drugs with no legal status</li><li>Articles containing unverified chemical infoboxes</li><li>This page was last edited on 21 December 2025, at 07:30 (UTC) .</li><li>Text is available under the Creative Commons Attribution-ShareAlike 4.0 License ; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy . Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc. , a non-profit organization.</li><li>Privacy policy</li><li>Disclaimers</li><li>Contact Wikipedia</li><li>Legal & safety contacts</li><li>Code of Conduct</li><li>Developers</li><li>Statistics</li><li>Cookie statement</li><li>Mobile view</li>
  </ul>
</section>
<section class="peptide-source">
  <h2>Source</h2>
  <p><a href="https://pubchem.ncbi.nlm.nih.gov/compound/Cibinetide" rel="noopener noreferrer" target="_blank">https://pubchem.ncbi.nlm.nih.gov/compound/Cibinetide</a></p>
  <ul>
    <li># JavaScript is required...</li><li>Please enable Javascript in order to use PubChem website.</li>
  </ul>
</section>
<section class="peptide-source">
  <h2>Source</h2>
  <p><a href="https://clinicaltrials.gov/search?cond=&term=Cibinetide" rel="noopener noreferrer" target="_blank">https://clinicaltrials.gov/search?cond=&term=Cibinetide</a></p>
  <ul>
    <li>Study record managers: refer to the Data Element Definitions if submitting registration or results information.</li><li>Search for terms</li>
  </ul>
</section>
            <p class="disclaimer-link"><small>Back to the main peptide list: <a href="../peptides.html">Peptides Overview</a>.</small></p>
          </main>
          <footer>
            © MinMaxMuscle. Discipline builds the body. Systems keep it.
          </footer>
          <script src="../assets/js/script.js"></script>
        </body>
        </html>
